AB Science Announces That It Has Received the First Authorization to Resume Patient Enrollment in the Confirmatory Phase III Study of Masitinib (AB19001) in ALS

AB Science SA announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase III study of masitinib in amyotrophic lateral sclerosis (ALS). Masitinib is a orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases.